Capricor Therapeutics faces increasing legal pressure as multiple law firms launch class action lawsuits for securities law violations
Executive summary: Capricor Therapeutics is facing multiple class action lawsuits filed by various law firms alleging violations of securities laws, including Rule 10b-5. The legal challenges coincide with a critical FDA review extension for deramiocel, creating dual pressure from both the legal and regulatory fronts.
Who is involved: Capricor Therapeutics, Inc. (NASDAQ: CAPR), DJS Law Group, SBS Law, Robbins Geller Rudman & Dowd LLP, and Hagens Berman Sobol Shapiro LLP.
Likely next: A lead plaintiff will be appointed by the September 28, 2026, deadline, potentially formalizing the class action structure.
Capricor Therapeutics is facing a coordinated surge in legal challenges as several prominent law firms seek lead plaintiffs in securities fraud class actions. The litigation targets potential violations of the Securities Exchange Act of 1934, coinciding with critical regulatory review timelines for the company's drug candidate, deramiocel.
What's next — scenarios
Base Case: Lead plaintiff appointment (60%)
The court appoints a lead plaintiff following the Sept 28 deadline, formalizing the legal process.
- Appointment of lead plaintiff by court before end of September 2026
Upside: Settlement agreement (25%)
Capricor reaches a settlement to avoid prolonged litigation and regulatory scrutiny.
- Positive FDA news regarding deramiocel
- Settlement announcement from Capricor
Downside: Severity of legal/regulatory convergence (15%)
Simultaneous FDA setbacks and escalating lawsuit damages increase financial instability.
- Negative FDA decision on deramiocel
- Expansion of class action scope
What to watch
- September 28, 2026: Deadline for investors to apply as lead plaintiffs
- FDA review decisions regarding deramiocel
Timeline
- — Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
- — Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026: Lead plaintiff application deadline
Sectors affected
- Biotechnology
- Pharmaceuticals
- Legal Services
Regulatory implications
- FDA review extension for deramiocel
Historical parallels
- Securities class actions following regulatory delays
Key entities
Sources
- Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR — PR Newswire
- Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline — PR Newswire
Related cases
- Cogent Communications faces mounting legal pressure as multiple law firms initiate securities fraud class actions
- Bloom Energy Corporation faces class action lawsuit over alleged securities law violations
- Capricor Therapeutics faces growing legal pressure as investors approach deadline for class action leadership amidst FDA review uncertainties
- Law firm Faruqi & Faruqi calls for lead plaintiffs in Capricor Therapeutics securities class action ahead of September 28 deadline
- Legal deadline looms for Capricor Therapeutics investors as class action lawsuit seeks lead plaintiffs for securities fraud claims
- Capricor Therapeutics faces a looming lead plaintiff deadline that could shape the outcome of its securities class action lawsuit